Larimar Therapeutics, Inc. Profile Avatar - Palmy Investing

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical tria…

Biotechnology
US, Bala Cynwyd [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Larimar Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of LRMR's Analysis
CIK: 1374690 CUSIP: 517125100 ISIN: US5171251003 LEI: - UEI: -
Secondary Listings
LRMR has no secondary listings inside our databases.